Keyphrases
CD4+
100%
CD8+
100%
Epitope
100%
High-risk Human Papillomavirus (HR-HPV)
100%
Early Protein
100%
Epitope Vaccine
100%
Immunogenicity
42%
Interferon-γ
42%
Population Coverage
28%
Cervical Cancer
28%
Therapeutic Efficiency
28%
Immunogenic Epitopes
28%
HPV-45
28%
Europe
14%
North America
14%
Cyclooxygenase-2
14%
Core Simulator
14%
Signaling Pathway
14%
MHC Class II
14%
CD8+ T
14%
Protein Sequence
14%
Antigenicity
14%
Immunogenic
14%
Binding Affinity
14%
Type-specific
14%
Vaccine Development
14%
East Asia
14%
Prophylactic Vaccine
14%
North Africa
14%
Overlapping Segments
14%
Cross-protection
14%
E2 Protein
14%
Conservancy
14%
Global Energy
14%
Systems Biology
14%
Target Receptor
14%
Potential Species
14%
B-cell Epitope
14%
Receptor Binding Affinity
14%
Human Papillomavirus Vaccine
14%
E1 Protein
14%
Linear B-cell Epitope
14%
E6 Protein
14%
West Indies
14%
E5 Protein
14%
Virtual Pathways
14%
Allergenicity
14%
E7 Protein
14%
Population Target
14%
Immunoinformatics Tools
14%
Sensitization Study
14%
Biochemistry, Genetics and Molecular Biology
CD8
100%
CD4
100%
Wart Virus
100%
Early Protein
100%
Late Protein
100%
Interferon Gamma
50%
Immunogenicity
50%
B Cell
33%
Binding Affinity
33%
Human Papillomavirus Type 45
33%
Signal Transduction
16%
P53
16%
Peptide Sequence
16%
T Cell
16%
Sensitization
16%
Receptor Binding
16%
Major Histocompatibility Complex
16%
Antigenicity
16%
Cross Protection
16%
Allergenicity
16%
Immunology and Microbiology
Vaccine Efficacy
100%
Epitope
100%
CD4
100%
CD8
100%
Wart Virus
100%
Immunogenicity
25%
Interferon Gamma
25%
B Cell
16%
Binding Affinity
16%
Human Papillomavirus Type 45
16%
Signal Transduction
8%
P53
8%
Cytotoxic T-Cell
8%
Major Histocompatibility Complex
8%
Antigenicity
8%
Amino Acid Sequence
8%
Sensitization
8%
Receptor Binding
8%
Cross Protection
8%
Cervarix
8%
Allergenicity
8%
Pharmacology, Toxicology and Pharmaceutical Science
Epitope
100%
Human Papillomavirus
100%
CD8 Antigen
100%
Gamma Interferon
25%
Immunogenicity
25%
Uterine Cervix Cancer
16%
Human Papillomavirus Type 45
16%
Receptor
8%
Infection
8%
Carcinogen
8%
Protein P53
8%
Vaccine Development
8%
Protein E6
8%
Wart Virus Vaccine
8%
Protein E7
8%
Glycoprotein E1
8%